Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganoderic acid A is a triterpenoid compound found primarily in the fruiting bodies of Ganoderma lucidum and related species such as Ganoderma sinense and Wolfiporia cocos. It is one of the most abundant and well-studied triterpenoids in these medicinal mushrooms. Mechanistically, ganoderic acid A exhibits multiple biological activities including antinociceptive (pain-relieving), antioxidative, cytotoxic (anti-cancer), hepatoprotective (liver-protecting), and neuroprotective effects. Its anticancer activity has been linked to cytotoxicity against tumor cells and modulation of oxidative stress pathways. In preclinical studies it has shown potential for use in conditions such as cancer and Alzheimer's disease by reducing mitochondrial damage induced by amyloid-beta peptides[2][3][4][5]. The metabolism of ganoderic acid A involves extensive phase I and II biotransformation primarily via CYP3A isoenzymes[2]. It is not an approved pharmaceutical drug but is widely studied for its pharmacological properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ganoderic acid a.